The ELANE–PRTN3 specificity was not as apparent in the lung cancer dataset, whereas the breast cancer dataset showed an anticorrelation between ELANE expression and intensity of nontryptic peptides cleaved at A, I, and V residues (the number of cases in that sample set with inflammatory breast cancer was not stated). This evidence concerns the gene PRTN3 and inflammatory breast carcinoma.